Losartan Potassium
Product Images NDC 71335-0698

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350698)

This text contains information on a medication called Losartan, in the form of a green oval tablet with the imprint E46, which contains 50mg of potassium. It is recommended to keep all drugs out of reach of children and to store this medication at room temperature between 20°-25°C (68° T7°F). It comes in a container holding 30 tablets and has a National Drug Code (NDC) of 7133506981 04238301523487. There is also a mention of Buyant Ranch Prcpach Bunbank on the same page, but it is unclear what this is referring to.*

FDA Label Image

Figure 1 (Losartan Fig1)

This is a data table showing the percentage of patients who achieved the primary endpoint in a study comparing Atenolol and Losartan Potassium. The adjusted risk reduction for the primary endpoint was found to be 13%, with a statistically significant p-value of 0.021. The study was conducted for a period of 66 months and the results were recorded at regular intervals of every 6 months.*

FDA Label Image

Figure 2 (Losartan Fig2)

This text appears to describe a comparison study of the medications Atenolol and Losartan Potassium. It mentions some kind of risk reduction percentage and a p-value of 0.001. It also appears to show a timeline in months for the study. However, without further context, it is difficult to determine the specifics of the study's findings or what the risk reduction percentage refers to.*

FDA Label Image

Figure 3 (Losartan Fig3)

This appears to be a table or chart of some sort related to demographic subgroups and their incidence of a primary endpoint event. The table includes data for different age groups, genders, races, and other factors such as potassium levels and history of VD. However, as some of the text is not easily readable due to errors, a more detailed description cannot be provided.*

FDA Label Image

Figure-4 (Losartan Fig4)

This text represents the results of a clinical trial comparing the use of Losartan Potassium with a placebo in a group of patients. The data shows that out of a total of 100 patients, 60 patients treated with Losartan had a positive outcome (referred to as an "event") while only 40 of those who received the placebo did. This translates into a risk reduction percentage of 16.1%. The p-value, which indicates the statistical significance of the observed difference, is 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.